Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year. The Financial Times reported the drugmaker has secured deals to provide COVID ...

Ridgeback and Merck have partnered to develop molnupiravir and will share profits. In some of the children Denison treats as the director of pediatric infectious diseases at VUMC, remdesivir ...

There’s a new drug in the wings to treat Covid, an at-home treatment called molnupiravir. Merck Pharmaceutical’s new “Covid pill” will supposedly be accessible medicine to treat ...

Merck already has a supply deal in place for molnupiravir with the US government, which has agreed a $1.2 billion order for 1.7 million doses at a price of $700 per course, as well as deals with ...

While Merck's oral drug Molnupiravir has already been cleared by the United Kingdom to treat COVID-19, a Paraguayan laboratory has filed for its emergency registration in the South American ...

Laboratory studies show that Merck & Co's experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant ...

Merck & Co and Ridgeback's oral antiviral molnupiravir has been approved in its first market – the UK – as a treatment for people with mild to moderate COVID-19 who are at increased risk of ...

This article was initially published on Wednesday and has been updated on Thursday after the FDA authorized Merck's antiviral pill molnupiravir. Read next ...

The Food and Drug Administration announcement on Merck's molnupiravir comes one day after the agency cleared a competing drug from Pfizer. Pfizer's pill, Paxlovid, is likely to become the first ...